Russia set for new wave of drug shortages

30 November 2021

Russia may face a new wave of shortage of drugs against coronavirus, influenza and acute respiratory viral infections (ARVIs), as the seasonal demand for them is rising, according to recent warnings by experts of the Federal Service for Surveillance in Healthcare (Roszdravnadzor) and local analysts.

So far, several regions of Russia are already faced with a shortage of such drugs and the growth of prices for them will be at least 5%-10% already in a short-term

The situation is also complicated by the fact that prices for a number of popular drugs that are not on the list of vital medicines in January-June of the current year grew by an average of 25%

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK